Home > Boards > US Listed > Medical - Drugs > Merck & Co. Inc. (MRK)

Pressure for the move is build !

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
wagner Member Profile
 
Followed By 13
Posts 1,677
Boards Moderated 0
Alias Born 04/20/10
160x600 placeholder
Drug Firms Sue Over Ad Rule -- WSJ Dow Jones News - 6/15/2019 3:02:00 AM
Drugmakers Sue to Block Federal Rule Requiring Drug Prices in TV Ads Dow Jones News - 6/14/2019 6:27:00 PM
IBM, KPMG, Merck and Walmart to collaborate as part of FDA's program to evaluate the use of blockchain to protect pharmaceuti... PR Newswire (US) - 6/13/2019 8:05:00 AM
FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab) Business Wire - 6/11/2019 6:45:00 AM
Merck to Buy Tilos Therapeutics for Up to $773 Million Dow Jones News - 6/10/2019 7:37:00 AM
Merck to Acquire Tilos Therapeutics Business Wire - 6/10/2019 6:45:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 5:22:33 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 5:21:55 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 5:21:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 5:21:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 5:20:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 5:20:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 5:20:33 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 5:20:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 5:19:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 5:19:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 5:19:01 PM
FDA Approves Merck’s ZERBAXA® (ceftolozane & tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired & Vent... Business Wire - 6/3/2019 4:55:00 PM
LYNPARZA® (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Rela... Business Wire - 6/3/2019 4:15:00 PM
AstraZeneca Lynparza Trial Results 'Unprecedented' Dow Jones News - 6/3/2019 2:48:00 AM
LYNPARZA® (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 ... Business Wire - 6/2/2019 7:30:00 AM
Five-Year Survival Data for Merck’s KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer (NSCLC) from First KE... Business Wire - 6/1/2019 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/31/2019 10:56:14 AM
Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastati... Business Wire - 5/31/2019 6:45:00 AM
Johnson & Johnson Weighs on Pharmaceutical ETFs Dow Jones News - 5/29/2019 2:30:00 PM
wagner   Wednesday, 01/30/19 10:54:02 AM
Re: None
Post # of 466 
Pressure for the move is build !

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist